Member Info for Laura2022

Absolutely...I'll be adding even more now ...very detailed and professional update

Excellent news

1.48p was the buy price at the time

Be interesting to see if he clears his name, in the shirt time I've seen SRT mentioned he seems to over promise and under deliver

Thanks msuk

If people can invest rather than trade it will be ideal

Eg someone bought ladt thing on Friday and sold 1st thing Monday for a loss,yet 2 days later it orse 15% more ...silly

This almost describes perfectly PYC target market

With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."

 

The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer drug helps to maximise DNA damage and selectively kill cancer cells. This provides a targeted approach to cancer treatment with the potential to improve patient outcomes across multiple tumour types.

Interesting developments at fellow bio tech AGL

Could well be PYC next to form this type of partnership? (Alongsode our work with merck)

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR

Yes Mark

The price is due to breakout this week amd this has been coupled with block buying all week ...

There has been NO holdings RNSs ďeapite 60% institutional holdings

In fact only one since Feb has been a USA fund increasing

Yes

If you look at the psots from 2 weeks ago 12-15p was initially target

RQIH 10p+ (cureent 3p)

PYC 5p+ (current 1.5p)

SAR now 230% up from purchases

Thanks Ralph

That's really kind mropz

They said the same on SND at 3p (now 4.5p)

Ignore the doomsters

Well done Mr calm

You'll like the other 2 also ( rqih and pyc)

Well done Mr calm

You'll like the other 2 also ( rqih and pyc)

Due to the low free-float thin-will move quickly

RQIH and PYC have identical charts to what SND had at 3.3p

Was buying SND at 3 2p/3 3p and now nearly 40% up with more left to go up

10p has always been the bare minumun (see previous posts)

RQIH 3p and worth 40p!! On asset sale

SAR up 200% since i bought at 10p

SND RQIH PYC the next 3 big movers

Equivalent of 50p+

Buying has been good this week, finally is this great company going to be recognised in an AIM world where huge indebted comapnies ĺike BMN and Hzm are faltering

We flagged this up at 3 2p 2 weeks ago

It's looking good now

Thanks to Smartmoney and scorcer etc

SND moving and RQIH will follow